Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Size is USD 198.82 Million in 2026

The global blood-based biomarker market for Alzheimer’s diagnostics, valued at USD 169.25 million in 2025, is projected to reach USD 846.83 million by 2035, growing at a CAGR of 17.47%, driven by rising demand for early, non-invasive detection solutions.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Statical Scope

The blood-based biomarker for alzheimer’s disease diagnostics resembles the proteins and is termed a peripheral indicator. The involvement of biomarkers like tau tangles and amyloid plaques is charted and precise in the AT (N) framework (Amyloid, Tau, and Neurodegeneration). The overall detection of these indicators needs mass spectrometry and robust ultra-sensitive technologies like Simoa.

The growing FDA’s green signal and access to new disease-modifying therapies are accelerating market expansion in the healthcare sector. The surge in blood tests introduces affordable alternatives necessary for proceeding with the anti-amyloid therapies. The recent FDA qualification of Fujirebio’s pTau217/β-amyloid test is a remarkable transition in clinical use, encouraging clinical performance.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Share, By Region, 2025 (%)

• North America – The North America regional segment dominated the market by 44% profit with its high investment and position in the Alzheimer’s research sector. The growing prevalence of Alzheimer's pushes the region towards enhancing the diagnostic tools.
• Europe – Europe covers 25% of the market share, with the tech innovations involving the use of valuable ratios and p-tau217. The clinical execution, harnessing to the new European guidelines, polishes the triaging tool with more accuracy.
• Asia Pacific – The segment leads with 18% share due to the heavy government investments in the Alzheimer’s programs and early detection. The growing number of dementia cases and the effective promotion of non-invasive procedures are strengthening the regional market.
• Latin America – Latin America covers 8% of the share, with the growing demand for non-invasive, affordable options for advanced lumbar punctures and PET scans. The groundbreaking diagnostics with the excellent participants' involvement covering sub-regions spur the growth and advancement in the region.
• Middle East & Africa – MEA region leads with 5% of share, with its robust healthcare infrastructure development. The automated platforms and lab-on-chip technology bring accuracy in testing and strengthen the regional market growth.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Share, By Type, 2025 (%)

• Neurodegeneration – The neurodegeneration segment is ahead with 30% of market share, with the dominance of popular NfL. The numerous blood-related biomarkers of neurodegeneration are accelerating the segmental growth.
• Amyloid-related markers – The segment covers 28% of the share with its great command of technologies like mass spectrometry and immunochemistry. This boosts the diagnostic portfolio and stimulates the segmental growth.
• Tau-related markers – The segment leads acquires 22% with the robust potential of the p-tau, p-tau181, p-tau231, and t-tau. The FDA clearance fuels more power in the clinical practices and encourages the best solution in the market.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Share, By Technology, 2025 (%)

• Immunoassays – The Immunoassays technology segment successfully acquires 35% of the share, with more power to ultrasensitive immunoassays, spotting low-abundance proteins. This technology is ideal for early diagnosis.
• Mass spectrometry-based assays – The segment covers 27% of the value due to the rising sensitivity in investigating low-concentration analytes. The growing clinical adoption featuring CLIA-certified assays elevates the segmental growth.
• Next-generation platforms – The segment is fueled by 23% with the growing demand for advanced technologies, highlighting AI-influenced analytics, microfluids, and lab-on-a-chip advancements. The accuracy of blood tests leverages quality monitoring, treatment, and screening.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Share, By End Use, 2025 (%)

• Clinical laboratories & hospital labs – The segment successfully acquires 50% of market share as hospital labs are the center of amyloid-β (Aβ) and p-tau217 immunoassays for hassle-free, smooth testing. The growing need for non-invasive, available best-in-class testing is elevating the segment growth.
• Pharma & biotech – The segment leads by 25% with its commendable pharmaceutical integration and technological advancements. The market leaders are constantly commercializing these robust technologies, complying with market needs.
• Academic & research institutes – The segment acquires 20% of the market share with the major advancements in performance in detecting p-tau181, NfL, and amyloid-β. The analytical boon aiming at research’s sincerity in the operation of mass spectrometry and ultra-sensitive immunoassays accelerates more growth in this segment.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Companies

• F. Hoffmann-La Roche Ltd
• Quanterix
• Fujirebio
• C2N Diagnostics
• Labcorp
• Quest Diagnostics Incorporated
• Siemens Healthineers
• Lilly USA, LLC
• Abbott
• ALZpath

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Segmentation

By Type

• Amyloid-related markers
• Tau-related markers
• Neurodegeneration

By Technology

• Immunoassays
• Mass spectrometry-based assays
• Next-generation platforms

By End-use

• Clinical laboratories & hospital labs
• Pharma & biotech
• Academic & research institutes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa